Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)

Abstract

Chronic NK lymphoproliferative disease of large granular lymphocytes (LDGL) is characterized by the expansion of activated CD3, CD16+ or CD56+ lymphocytes. The mechanism of survival of NK cells from LDGL patients is unknown but may be related to antigenic stimulation. There is currently no standard effective therapy for LDGL, and the disease is characteristically resistant to standard forms of chemotherapy. We found evidence of constitutive activation of extracellular-regulated kinase (ERK) in NK cells from 13/13 patients with NK-LDGL (one patient with aggressive and 12 patients with chronic disease). Ablation of ERK activity by inhibitors or a dominant-negative form of MEK, the upstream activator of ERK, reduced the survival of patient NK cells. Ras was also constitutively active in patient NK cells, and exposure of cells to the Ras inhibitor FTI2153 or to dominant-negative-Ras resulted not only in ERK inhibition but also in enhanced apoptosis in both the presence and absence of anti-Fas. Therefore, we conclude that a constitutively active Ras/MEK/ERK pathway contributes to the accumulation of NK cells in patients with NK-LDGL. These findings suggest that strategies to inhibit this signaling pathway may be useful for the treatment of the NK type of LDGL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR . (1995). J. Biol. Chem., 270, 27489–27494.

  • Chang L and Karin M . (2001). Nature, 410, 37–40.

  • Cohen JJ, Duke RC, Fadok VA and Sellins KS . (1992). Annu. Rev. Immunol., 10, 267–293.

  • Djeu JY, Jiang K and Wei S . (2002). Clin. Cancer Res., 8, 636–640.

  • Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R and Loughran Jr TP . (2001). J. Clin. Invest., 107, 351–362.

  • Epling-Burnette PK, Painter JS, Chaurasia P, Bai F, Wei S, Djeu JY and Loughran TP . (2004). Blood, 103, 3431–3439.

  • Ferlazzo G, Morandi B, D'Agostino A, Meazza R, Melioli G, Moretta A and Moretta L . (2003). Eur. J. Immunol., 33, 306–313.

  • He T, Stepulak A, Holmstrom TH, Omary MB and Eriksson JE . (2002). J. Biol. Chem., 277, 10767–10774.

  • Holmstrom TH, Schmitz I, Soderstrom TS, Poukkula M, Johnson VL, Chow SC, Krammer PH and Eriksson JE . (2000). EMBO J., 19, 5418–5428.

  • Husain Z, Alper CA, Yunis EJ and Dubey DP . (2002). Immunology, 106, 373–380.

  • Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S and Djeu JY . (2000). Nat. Immunol., 1, 419–425.

  • Lamy T, Liu JH, Landowski TH, Dalton WS and Loughran Jr TP . (1998). Blood, 92, 4771–4777.

  • Lanier LL, Cwirla S, Federspiel N and Phillips JH . (1986). J. Exp. Med., 163, 209–214.

  • Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD and Sebti SM . (1995). J. Biol. Chem., 270, 26802–26806.

  • Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD and Sebti SM . (1997). Oncogene., 15, 1283–1288.

  • Lima M, Almeida J, dos Anjos Teixeira M, Queiros ML, Justica B and Orfao A . (2002). Blood Cells Mol. Dis., 28, 181–190.

  • Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B and Schlessinger J . (1993). Nature, 363, 85–88.

  • Loughran Jr TP . (1993). Blood, 82, 1–14.

  • Loughran Jr TP, Hadlock KG, Yang Q, Perzova R, Zambello R, Semenzato G, Foung SK and Poiesz BJ . (1997). Blood, 90, 1977–1981.

  • Loughran Jr TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, Lum LG and Slichter SJ . (1985). Ann. Intern. Med., 102, 169–175.

  • Loughran Jr TP, Sherman MP, Ruscetti FW, Frey S, Coyle T, Montagna RA, Jones B, Starkebaum G and Poiesz BJ . (1994). Leuk. Res., 18, 423–429.

  • McVicar DW and Burshtyn DN . (2001). Sci. STKE, 2001, RE1.

  • Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S and Taniguchi N . (1992). J. Immunol., 149, 3753–3758.

  • Montagna D, Moretta A, Marconi M, Mingrat G, Gasparoni A, Giarola M and Maccario R . (1992). Biol. Neonate, 62, 385–394.

  • Ohno T, Kanoh T, Arita Y, Fujii H, Kuribayashi K, Masuda T, Horiguchi Y, Taniwaki M, Nosaka T, Hatanaka M and Uchino I . (1988). Cancer, 62, 1918–1927.

  • Ortaldo JR, Mason AT and O'Shea JJ . (1995). J. Exp. Med., 181, 339–344.

  • Perzova RN, Loughran TP, Dube S, Ferrer J, Esteban E and Poiesz BJ . (2000). Br. J. Haematol., 109, 64–70.

  • Ritz J, Campen TJ, Schmidt RE, Royer HD, Hercend T, Hussey RE and Reinherz EL . (1985). Science, 228, 1540–1543.

  • Scheid MP, Schubert KM and Duronio V . (1999). J. Biol. Chem., 274, 31108–31113.

  • Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, Trentin L, Agostini C, Dini E, Vespignani M, Cafaro A, Pasqualetti D, Giubellino C, Migone N and Foa R . (1987). Cancer, 60, 2971–2978.

  • Soderstrom TS, Poukkula M, Holmstrom TH, Heiskanen KM and Eriksson JE . (2002). J. Immunol., 169, 2851–2860.

  • Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD and Sebti SM . (1999). Cancer Res., 59, 4919–4926.

  • Takahashi A, Day NK, Luangwedchakarn V, Good RA and Haraguchi S . (2001). J. Immunol., 166, 6771–6775.

  • Taniwaki M, Tagawa S, Nishigaki H, Horiike S, Misawa S, Shimazaki C, Maekawa T, Fujii H, Kitani T and Abe T . (1990). Am. J. Hematol., 33, 32–38.

  • Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH and Phyliky RL . (1994). Blood, 84, 2721–2725.

  • Timonen T, Ortaldo JR and Herberman RB . (1981). J. Exp. Med., 153, 569–582.

  • Tran SE, Holmstrom TH, Ahonen M, Kahari VM and Eriksson JE . (2001). J. Biol. Chem., 276, 16484–16490.

  • Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA and Nagata S . (1992). Nature, 356, 314–317.

  • Wei S, Gamero AM, Liu JH, Daulton AA, Valkov NI, Trapani JA, Larner AC, Weber MJ and Djeu JY . (1998). J. Exp. Med., 187, 1753–1765.

  • Wei S, Gilvary DL, Corliss BC, Sebti S, Sun J, Straus DB, Leibson PJ, Trapani JA, Hamilton AD, Weber MJ and Djeu JY . (2000). J. Immunol., 165, 3811–3819.

  • Zingoni A, Palmieri G, Morrone S, Carretero M, Lopez-Botel M, Piccoli M, Frati L and Santoni A . (2000). Eur. J. Immunol., 30, 644–651.

Download references

Acknowledgements

This work was supported by the following grants: Veterans' Administration Hospital and National Institute of Health Grants AI056213, CA90633, CA83146, CA83947, and CA94872. We would like to thank the Flow Cytometry Core and Molecular Imaging Core Facilities at H Lee Moffitt Cancer Center for assistance with data analysis and preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pearlie K Epling-Burnette.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Epling-Burnette, P., Bai, F., Wei, S. et al. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 23, 9220–9229 (2004). https://doi.org/10.1038/sj.onc.1208122

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208122

Keywords

This article is cited by

Search

Quick links